DDW ARTICLE DATABASE

THIS MONTH'S LIFE SCIENCE MOVIES
Superheroes
Waters ionKey/MS
With an ionKey/MS System, Waters transforms what your lab can do.
Watch Video
Waters
Bioanalysis of Oxytocin
Ultrasensitive Quantification Assay for Oxytocin in Human Plasma Using an LC/MS Microfluidics Platform
Watch Video
Latest Articles

Building new models of drug discovery in Europe the Innovative Medicines Initiative

By Dr Angela Wittelsberger, Dr Hugh Laverty and Dr Michel Goldman
The development of a new medicine is risky and expensive. It often takes 15 years and a $1billion investment for a compound to navigate its way along the development process. Only 8% of candidates make it to market and benefiting the patient.
 

Collaboration for innovation is the new mantra for the pharmaceutical industry

By Professor Jackie Hunter
In order to maintain a flow of innovative medicines there is a growing realisation that companies cannot allow the status quo to remain. The need to identify sources of knowledge and expertise outside of their own organisations is paramount.
 

Could the keys to precision and personalised medicine be rooted in predictive safety and research methods?

By Robert G. Hunter
To meet the massive challenges of future healthcare, perhaps no two facets hold greater promise than biomarkers for precision medicine and systems biology for personalised patient care.
 

Developing the first treatment for Acute Kidney Injury

By Tim Knotnerus
Acute Kidney Injury (AKI) is a devastating disease characterised by a rapid loss of kidney function resulting in inability to maintain fluid, electrolyte and acidbase balance. AKI is particularly common in patients admitted to the Intensive Care Unit where incidence rates between 22% to as high as 67% of admissions have been reported.
 

How digital innovation and collaboration is driving a global demand for effective reporting in research funding

By Frances Buck
The UK, Europe and the US are world leaders in research and innovation. They have world-leading universities, research institutes and scientific enterprises, supported by a public and private sector that has continued to invest, despite the global economic downturn.
 

Long live peptides evolution of peptide half-life extension technologies and emerging hybrid approaches

By Dr Ronald V. Swanson
Among therapeutic modalities, peptides occupy a middle ground between traditional ‘small molecule’ drugs and the larger injectable biologics, not fitting comfortably into either category.
 

Rules for drug discovery: can simple property criteria help you to find a drug?

By Dr Matthew Segall
Since publication of Lipinski’s Rule of Five (Ro5) in 1997 we have seen the growth of a minor industry dedicated to generating new ‘rules’ for drug discovery. Fuelled by “Ro5 envy”, these rules are usually based on simple calculated compound characteristics and define criteria for the selection of compounds in drug discovery. But, can a generic rule be used to reliably select compounds for drug discovery?
 

The current status of non-biopharma drug discovery

By Dr John Comley
Screening centres in academic institutions and non-profit organisations have become an established mechanism to exploit novel targets and neglected diseases and to identify chemical probes. Where centres have a disease focus, their main expertise resides in cancer and phenotypic screens, with screening experience greatest for kinases, phenotypic approaches and protein-protein interactions.
 




Easier diagnosis of Creutzfeldt-Jakob disease discovered

August 2014
BMG LABTECH’s microplate reader FLUOstar® Omega has helped researchers to develop a reliable, safer and less invasive method for the diagnosis of prion diseases
 

Easier diagnosis of Creutzfeldt-Jakob disease discovered

August 2014
BMG LABTECH’s microplate reader FLUOstar® Omega has helped researchers to develop a reliable, safer and less invasive method for the diagnosis of prion diseases
 

Improve Gene Expression Results with Bio-Rad’s New Rapid Cell Lysis RT-qPCR Kits

August 2014
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of new rapid cell lysis kits
 

Optibrium Launches SentiraTM: New Software for Compound Data Visualisation

August 2014
Powerful desktop application simplifies visualisation, interpretation and presentation of compound dataPowerful desktop application simplifies visualisation, interpretation and presentation of compound data
 

New Sensitive Amp’d™ GLP-1 ELISA Kit for the Rapid Detection of Glucagon-Like Peptide 1

July 2014
Strengthening our leadership position in immunoassays, Enzo Life Sciences now offers Amp'd™ GLP-1 ELISA Kit
 

NEW iPad App for TAP’s ambr15 Automated Micro Bioreactor System

July 2014
Provides Simple to Use, Downloadable iBrochure Packed with Applications and Benefits